WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > BioSTL
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Cell and Gene Therapy
Fulgent Genetics, Inc. | February 24, 2022
Fulgent Genetics, Inc. a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced a strategic investment in Spatial Genomics, Inc. a leading developer of sequential fluorescence in situ hybridization technology. Fulgent Genetics is investing up to $40 million to lead Spatial Genomics’ Series A financing, which totals approximately $56 million and also includes investments by 12 West Cap...
PR Newswire | August 21, 2020
CDI Laboratories, Inc. announced the addition of its SARS-CoV-2 (COVID19) assay platform. The assays use CDI's VirScan service which can detect antibodies to 1345 individual viral strains representing species from 76 viral genera. This is coupled with CDI's 2 in 1 SARS-CoV-2 antigen microarray which contains overlapping SARS-CoV-2 peptides as well as full-length proteins. This will allow researchers, therapeutic developers, and vaccine developers, to analyze human serum for all kno...
Industry Outlook
Applied Microarrays Inc. | September 30, 2021
SCHOTT MINIFAB, a subsidiary of SCHOTT that develops and manufactures microfluidic devices for point-of-care and life sciences consumables, has had a long-standing close customer relationship with Applied Microarrays Inc. (AMI). Together, they develop biotech substrates for diagnostics applications. The expertise of AMI will further strengthen SCHOTT’s ability to offer a single-source contract manufacturing solution. The deal is expected to close in early October. Through th...
BioMarin | May 03, 2020
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has entered into a preclinical collaboration and license agreement with DiNAQOR AG (DiNAQOR), a gene therapy platform company, to develop novel gene therapies to treat rare genetic cardiomyopathies. DiNAQOR will receive an undisclosed upfront payment and is eligible to receive development, regulatory and commercial milestones on product sales in addition to tiered royalties on worldwide sales. The company did not ...
Medical
Whitepaper
Cell and Gene Therapy, Industrial Impact
Medical, Industry Outlook
Industrial Impact, Medical
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE